Optiver Holding’s Prelude Therapeutics PRLD Stock Holding History

Optiver Holding’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$68	Hold	20	–	–	﹤0.01%	2252
2025 Q4	$58	Hold	20	–	–	﹤0.01%	2393
2025 Q3	$29	Buy	+20	New	+$20	﹤0.01%	2637

Other funds holding PRLD

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Optiver Holding's PRLD Position: Q1 2026 in Review

Optiver Holding held its Prelude Therapeutics (PRLD) position steady in Q1 2026 at 20 shares worth $68. The position accounts for ﹤0.01% of the portfolio, ranked #2252.

Optiver Holding first reported a position in PRLD in Q3 2025 and has held it in 3 quarters since. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

Optiver Holding held 20 shares of Prelude Therapeutics worth $68 as of Q1 2026.
Optiver Holding left its Prelude Therapeutics share count unchanged in Q1 2026.
Prelude Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q1 2026, its #2252 holding.
Optiver Holding first reported a position in Prelude Therapeutics in Q3 2025 and has held it in 3 quarters since.
55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.